SHR7280

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

EndometriosisHealthy SubjectsHormone Sensitive Prostate Cancer

Phase 1

The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.

CompletedNCT04417972

Jiangsu HengRui Medicine Co., Ltd.Endometriosis

Start: 2020-07-30End: 2024-05-14Updated: 2024-07-08

The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

CompletedNCT04554043

Jiangsu HengRui Medicine Co., Ltd.Healthy Subjects

Start: 2020-09-11End: 2021-09-28Updated: 2021-10-28

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

CompletedNCT04995042

Jiangsu HengRui Medicine Co., Ltd.Hormone Sensitive Prostate Cancer

Start: 2021-09-24End: 2023-05-25Updated: 2023-09-21

Related Papers

Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

2023-10-142 citations

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study.

2023-04-032 citations

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women

Frontiers in Pharmacology2022-11-236 citations